Matt Cohen
440 posts
Matt Cohen
@mcohenOUP
Managing Partner, Osage University Partners, Life Science VC @OUP_VC. PhD, recovering management consultant
Philadelphia Katılım Aralık 2008
319 Takip Edilen284 Takipçiler
@oakazaki @plainyogurt21 I also wondered about this. You might expect insomnia AEs if that was the case, though. Could it be something as simple as more total pills (drug or placebo) given at the higher dose? Could also just be noise with small n. 🤷
English
@plainyogurt21 do you know how long the washout period is? can't find it quickly. Is it possible the high dose stays on board through washout, contributing to the higher PBO effect at 2.5mg?
English
$CNTA, results look pretty good. Comparable to ALKS with less AEs.
English
@oakazaki @plainyogurt21 Sleep deprived HVs weren’t tested at the middle dose. It’s in the footnote.
English
@plainyogurt21 ha. totally forgot about the lack of efficacy data on the middle dose....somehow the found the safety data though...
English
Thrilled to support S2S and all of the incredible academic innovation being showcased. #Science2Startup
Osage Univ. Partners@OUP_VC
OUP's @mcohenOUP, Ph.D. will join researchers, entrepreneurs and top investors this May for the 3rd annual #Science2Startup! Learn more about the event and the how it is supporting the future of #biotech: science2startup.com
English
@debpalestrant @5amVentures Thanks, @debpalestrant ! @Mitra_DosM and I fully agree - best first meeting of JPM we could’ve had. Let’s make it a thing!
English
And thats a wrap for me! It was wonderful seeing so many folks here at #JPM23 and hosting so many great meetings in the @5amVentures suite! From the first meeting on Monday morning (@mcohenOUP) to end of today, it has been a wonderful few days! Looking forward to a great year!
English
Matt Cohen retweetledi
The first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens. It is our first internally discovered T cell medicine to enter clinical development: shorturl.at/iwT03
English
Matt Cohen retweetledi
I’ve received messages from many friends and colleagues asking how how they can donate to causes in memory of my wife, Renee, and daughters, Parker and June, since the accident last week. I posted a couple of ideas here: tinyurl.com/ymat8tfs
English
Matt Cohen retweetledi
#Science2Startup is a one-day symposium for therapeutics researchers to present startup ideas to leaders in the #biotech space on May 23, 2023 in Boston.
Apply here by December 5: science2startup.com
@FPrimeCapital @atlasventure @5amVentures @OUP_VC #RACapital
English
@ideapharma @AppleHelix @MenePangalos @LifeSciVC I agree that companies will withhold launch for indication expansion early and that’s not ideal for patients. And value data is good. Market access is one element. Physician comfort is another and that more time/use based than anything. Will be fascinating to watch.
English
@mcohenOUP @AppleHelix @MenePangalos @LifeSciVC I’ll ask the team for refreshed numbers. But main point is that averages corrupt planning. Securing value endpoint data (for market access) often is in tension with ‘simple’ approval data, so isn’t done. Indication strategy is often sequential vs portfolio approach.
East, England 🇬🇧 English
In 2010, Top 20 drugs in US treated 45M patients.
In 2020, Top 20 only treated 9M patients
But revenues up 25% because of prices (more expensive rarer/lower prevalence diseases )
McKinsey at #AtlasVentureRetreat
English
@ideapharma @AppleHelix @MenePangalos @LifeSciVC Thx. Has 13% of drug launches to peak in yr 3 gone up since 2018? Were these Medicare pop launches or rare disease with no other options? The data is interesting. What’s current avg across all launches in last 10 yrs? Would be interesting to see. I’m admittedly out of date
English
@mcohenOUP @AppleHelix @MenePangalos @LifeSciVC It’s from 2018, but I wrote this piece on the phenomenon linkedin.com/pulse/why-ever…
East, England 🇬🇧 English
@ideapharma @AppleHelix @MenePangalos @LifeSciVC Peak sales ramp in 3 year would be news to me. The assumptions I used building these forecasts based on data (10 years ago, admittedly), were 7 years on average. Is there any recently published data on this you could point me to?
English
@mcohenOUP @AppleHelix @MenePangalos @LifeSciVC All of your assumptions are wrong, so it might take more than a Twitter thread to answer your last one, especially if you think cos optimise launch vs approval. For example, >35% of small molecule launches in the past 5 years saw peak sales (and then decline) within 3 years.
East, England 🇬🇧 English
@ideapharma @AppleHelix @MenePangalos @LifeSciVC Every pharma company plans to launch. I’m not sure what you’re saying, tbh. The ramp avg is 7 years and it’s not due to a launch delay. Adoption is always slow. What do you mean by lifecycling earlier? What would you spend on earlier that helps maximize revenue before yr 9?
English
@mcohenOUP @AppleHelix @MenePangalos @LifeSciVC You plan to launch, not just get approval, so you maximise year 1. The launch hurdles are pretty predictable. Incyte, for example, recently went from approval to 1st commercial dose in <2 days.
And you start lifecycling way earlier.
East, England 🇬🇧 English
@ideapharma @AppleHelix @MenePangalos @LifeSciVC How do you improve launch ramps? They on average take 7 years or so to hit peak sales so the expectation is you are cutting ~50% off the sales potential given half of it comes in years 8-13. Lower R&D costs help NPV but not enough. How do you launch faster more widely?
English
@AppleHelix @MenePangalos @LifeSciVC True - as written it makes no sense. But it is a level playing field. Those companies who can do better work in early phases will be ready to maximise their 9 year curve, as there are real opportunities in the small molecule space being missed today
East, England 🇬🇧 English
Matt Cohen retweetledi
Matt Cohen retweetledi
Thrilled to see @HyalexOrtho appear on @BusinessInsider list of biotech startups to watch in next year. Excited to see what CEO @carl_vause and team accomplish. @WendeHutton @JuliePapanek @jesse_yeji
Read full piece with BI subscription at: businessinsider.com/list-top-biote…
English
@PearlF @ChrisHeery @michael_gilman I believe that was analysis done by @ohadhammer and from my recollection of what it was 10 years ago it’s up a lot. CROs and pass through costs from trial sites certainly aren’t getting cheaper.
English
@ChrisHeery @michael_gilman I also wonder what could bring the costs of clinical trials in the US down, I read that it costs $250k/per cancer patient in Phase 1/2—is this true?
English
No question our health care system is deeply flawed. But I've spent thirty years of my life and hundreds of millions of dollars trying to develop drugs. And I've completely failed. Maybe I'm just bad at it. Or maybe it's expensive and hard. We need to find a way to pay for it.
Naftali Kaminski@KaminskiMed
Drugs don't work if people cannot afford them - this is the answer to @steveubl threats. Shame on him and on @PhRMA. A call by >75 Groups including @AARP on Congress to Immediately pass #DrugPrice Reforms in #InflationReductionAct! #ThisIsOurLane patientsforaffordabledrugsnow.org/2022/08/05/pre…
English
@SaraNayeem @bernatolle @TauhidAli4 I’ve noticed that in some cases PB has been eerily accurate. This has been more recently, say in the last 6 months. My understanding is that they are now buying publicly available Delaware corporate filings and extracting data from the charters on valuation.
English
@bernatolle @TauhidAli4 I haven't seen information I knew to be wrong (most rounds have no valuation info), but I'll keep an eye out. I think it's a great resource for quickly seeing deal pace, getting a list of deals, but I always ask the company directly for their valuation.
English
@SaraNayeem Any plans to do a thread on private company valuations?
English